Need Help?
Copied to clipboard!

MP2PRT: Genomic and Molecular Characterization of Biomarkers Associated With Self-Reported Race/Ethnicity in High-Risk Endometrial Cancers From NRG Oncology/GOG Protocol 210, Molecular Staging of Endometrial Cancer (NCT00340808)

The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program. This study, titled “Genomic and molecular characterization of biomarkers associated with self-reported race/ethnicity in high-risk endometrial cancers from NRG Oncology/GOG Protocol 210, Molecular Staging of Endometrial Cancer (NCT00340808)”, is one of the selected studies under this program. For this study, genomic characterization (i.e., Whole Genome Sequencing (WGS), Total RNA-Seq, Ancestry Genotyping) was performed on endometrial tumor tissue and matching normal tissue previously collected from patients with high-risk endometrial cancer. It is hypothesized that there are distinct molecular markers that high-risk endometrial cancers possess that can be used to predict the risk of recurrence and death for those women and by reported standard of care therapies. It is also hypothesized that there will be differences in molecular finding between self-reported black and white women that may account for some of the differences in outcomes.